Rigel Pharmaceuticals Inc. (RIGL) announced Tuesday morning that fostamatinib met the primary endpoint in the first of two Phase 3 clinical studies for the treatment of adult chronic/persistent immune thrombocytopenia.
from RTT - Before the Bell http://ift.tt/2bRyMuN
via IFTTT
No comments:
Post a Comment